当前位置:
X-MOL 学术
›
J. Natl. Cancer Inst.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Precision preclinical modeling to advance cancer treatment
Journal of the National Cancer Institute ( IF 9.9 ) Pub Date : 2024-10-09 , DOI: 10.1093/jnci/djae249 David H Gutmann, Jesse S Boehm, Elinor K Karlsson, Eric Padron, Mukund Seshadri, Deann Wallis, Joshua C Snyder
Journal of the National Cancer Institute ( IF 9.9 ) Pub Date : 2024-10-09 , DOI: 10.1093/jnci/djae249 David H Gutmann, Jesse S Boehm, Elinor K Karlsson, Eric Padron, Mukund Seshadri, Deann Wallis, Joshua C Snyder
A new era of cancer management is underway in which treatments are being developed for the entire continuum of the disease process. The availability of genetically engineered and naturally occurring preclinical models serve as instructive platforms for evaluating therapeutic mechanisms. However, a major clinical challenge is that the entire malignancy process occurs across multiple scales including genetic mutations, malignant changes in cell behavior, dysregulated tumor microenvironments, and systemic adaptations in the host. A multi-disciplinary group of investigators coalesced at the National Cancer Institute Oncology Models Forum (NCI-OMF) with the overall goal to provide updates on the use of precision preclinical models of cancer. The benefits and limitations of preclinical models were discussed in order to identify strategies for maximizing opportunities in modeling that could inform future cancer prevention and treatment approaches. Our shared perspective is that the continuum of single cell, multi-cell, organoid, and in situ models are remarkable resources for the clinical challenges ahead. We provide a roadmap for parsing already available models and include preliminary recommendations for the application of next generation preclinical modeling in cancer intervention.
中文翻译:
精确的临床前建模以推进癌症治疗
癌症管理的新时代正在到来,正在为疾病过程的整个连续体开发治疗方法。基因工程和自然存在的临床前模型的可用性可作为评估治疗机制的指导平台。然而,一个主要的临床挑战是整个恶性肿瘤过程发生在多个尺度上,包括基因突变、细胞行为的恶性变化、失调的肿瘤微环境和宿主的全身适应。一个多学科研究人员小组在美国国家癌症研究所肿瘤模型论坛 (NCI-OMF) 上联合起来,其总体目标是提供有关癌症精确临床前模型使用的最新信息。讨论了临床前模型的优点和局限性,以确定最大限度地利用建模机会的策略,从而为未来的癌症预防和治疗方法提供信息。我们的共同观点是,单细胞、多细胞、类器官和原位模型的连续体是应对未来临床挑战的重要资源。我们提供了解析现有模型的路线图,并包括将下一代临床前建模应用于癌症干预的初步建议。
更新日期:2024-10-09
中文翻译:
精确的临床前建模以推进癌症治疗
癌症管理的新时代正在到来,正在为疾病过程的整个连续体开发治疗方法。基因工程和自然存在的临床前模型的可用性可作为评估治疗机制的指导平台。然而,一个主要的临床挑战是整个恶性肿瘤过程发生在多个尺度上,包括基因突变、细胞行为的恶性变化、失调的肿瘤微环境和宿主的全身适应。一个多学科研究人员小组在美国国家癌症研究所肿瘤模型论坛 (NCI-OMF) 上联合起来,其总体目标是提供有关癌症精确临床前模型使用的最新信息。讨论了临床前模型的优点和局限性,以确定最大限度地利用建模机会的策略,从而为未来的癌症预防和治疗方法提供信息。我们的共同观点是,单细胞、多细胞、类器官和原位模型的连续体是应对未来临床挑战的重要资源。我们提供了解析现有模型的路线图,并包括将下一代临床前建模应用于癌症干预的初步建议。